Concise Communication

Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients

Matthew W. Davis PharmD1,2,a, Dayna McManus PharmD1,2,a, Alan Koff MBBS2, Gregory R. Jaszczur PharmD3, Maricar Malinis MD2, Charles Dela Cruz MD, PhD4, Clemente J. Britto MD4, Christina Price MD5, Veronica Azmy MD5, Kelsey Kaman MD5, David Gaston MD, PhD2, Kevin Early PharmD3, Michelle DeWitt RN, BSN3, Ju-Sung Song PharmD3, Claudia Ortiz3, Manisha Juthani-Mehta MD2 and Jeffrey E. Topal MD1,2

1Department of Pharmacy Services, Yale New Haven Hospital, New Haven, Connecticut, 2Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, 3Information Technology Services, Yale New Haven Health System, New Haven, Connecticut, 4Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut and 5Section of Rheumatology, Allergy and Immunology, Yale University School of Medicine, New Haven, Connecticut

Abstract

During the COVID-19 pandemic, the antimicrobial stewardship module in our electronic medical record was reconfigured for the management of COVID-19 patients. This change allowed our subspecialist providers to review charts quickly to optimize potential therapy and management during the patient surge.

(Received 30 April 2020; accepted 3 June 2020; electronically published 8 June 2020)

In December of 2019, several cases of pneumonia of unknown etiology were recognized by the World Health Organization (WHO) in Wuhan City, Hubei Province, China.1 This pneumonia was rapidly identified to be caused by the SARS-CoV-2 virus and named coronavirus disease 2019 (COVID-19). The presence of human-to-human transmission was quickly recognized, and on March 11, 2020, COVID-19 was declared a pandemic by the WHO.2,3

In the United States, the first documented case of COVID-19 occurred in a 35-year-old man in Snohomish County, Washington, on January 19, 2020.4 Rapid spread subsequently occurred across the country, and as of April 23, the United States had recorded >800,000 cases and >44,000 deaths.5

Given the spread of this novel virus, hospitals have seen a rapid increase of COVID-19 patients in a short period. This surge has placed a strain on vital resources, including personal protective equipment (PPE), mechanical ventilators, and hospital personnel, including infectious disease consultants.

At Yale New Haven Hospital (YNHH), in anticipation of a surge in COVID-19 patients, a multidisciplinary team comprised of members from allergy and immunology, antimicrobial stewardship team (AST), hematology, infectious diseases, pharmacy, pulmonology, and critical care collaborated to provide guidance on potential treatments and management. One of the primary clinical challenges to be addressed was the increasing number of new COVID-19 patients each day. At the height of the surge, in our 1,500-bed hospital, we were caring for >450 patients with COVID-19. With this rapid increase, the number of total medical ICU beds was expanded from 56 to 131. Prior to the surge, our 4 inpatient infectious diseases consultants covered ~50 patients. However, during this time, the hospital staff requested subspecialty guidance for the management of COVID-19 patients. The number of patients with COVID-19 overwhelmed our ability to provide optimal subspecialty care. Given this increase, there was a significant need for a rapid assessment tool to review patients and to prioritize consultations.

Prior to the COVID-19 pandemic, the YNHH AST customized the antimicrobial stewardship (AMS) module in our electronic medical record (EMR; Epic, Verona, WI). This customized module facilitated efficient review of relevant clinical patient information to provide recommendations for optimizing antimicrobial use. The existing AMS accordion report contained information regarding vital signs, fever curve, intake and output, relevant hematology and chemistry laboratory values, microbiology results, radiology studies, medications, and allergies. Given the rapid increase in number of patients and the need to provide clinical oversight, a challenge similar to AMS, a revised version of this tool was proposed by the AST as a potential solution.

Herein, we describe our process of repurposing the AMS module and associated technology to optimize the management of COVID-19 patients.

Intervention

To identify COVID-19 patients in real time, with the help of the information technology (IT) team, 2 patient lists were created in...
the EMR. The first list comprised inpatients with positive COVID-19 results based on SARS-CoV-2 polymerase chain reaction assay (PCR). The second list identified patients who were suspected to be COVID-19 positive based on clinical presentation with a SARS-CoV-2 PCR in process. At YNHH, in-house SARS-CoV-2 PCR testing was initiated on March 13, 2020, which allowed for an initial turnaround time of 8–12 hours. Prior to this, SARS-CoV-2 tests were done through the Connecticut Department of Health. The validation of the in-house testing was timely because our first COVID-19–positive patient was admitted on March 12, 2020.

After the creation of the COVID-19 patient lists, additional modifications were made to specifically aid in the assessment of these patients. In addition to the standard columns within the patients list (ie, admission date, bed, unit, patient name, age, and gender), the following items were added to help rapidly identify patients with more severe disease: oxygen requirements, oxygen orders, and the presence of mechanical ventilation orders (Fig. 1, box 1). To further triage higher-acuity patients, a column delineating high-sensitivity C-reactive protein (hsCRP) levels was also created. A dynamic scoring column was built which would display a designated icon if patients had an hsCRP $\geq 70$ mg/L or an increase $\geq 30$ mg/L in the previous 24 hours (displayed as COVID-19 CRP). HsCRP can be elevated in the setting of the cytokine release syndrome phase of COVID-19, and it is a reliable indicator of disease severity (Fig. 1, box 1). Furthermore, the AMS accordion report described earlier was modified to also include COVID-19–specific information including inflammatory markers and potential treatment options.

A “COVID TRACKING time since review” column was incorporated into the patient list to display the amount of time since the patient was last reviewed (Fig. 1, box 2). If the patient had not been reviewed, then the phrase “never reviewed” was displayed in this column. When a patient was selected from the list, the optimized AMS accordion report would display relevant COVID-19 data so that the patient could be reviewed without the need to enter data into the electronic chart (Fig. 1, box 4). Within the accordion report, a document scoring system could be used as a hand-off tool to provide a brief synopsis of important factors and items to follow up in subsequent reviews (Fig. 1, box 3). The option to post to a progress note was available within the documentation screen if a specific recommendation needed to be placed into the patient’s chart to facilitate communication with the primary team. When the review was completed, the “COVID TRACKING time since review” column was automatically updated to help avoid duplicate reviews of the same patient.

Fig. 1. An image displaying the customized AMS module within our EMR, EPIC. Box 1 illustrates the columns added specifically for COVID-19; oxygen requirement, oxygen orders, vent order and high sensitivity CRP to triage higher acuity patients. Box 2 demonstrates the “COVID TRACKING Time Since Review” which shows the last time a patient has been reviewed to prioritize patients. Box 3 is the “Document System Scoring Report”, where documentation for follow-up items can be entered. Box 4 is part of the AMS accordion report which contains vital signs, fever curve, intake/output, relevant hematology and chemistry laboratory values, microbiology, radiology, medications and allergies. Due to space limitations, this is a snap shot of the report so not all of the available data is displayed. © 2020 Epic Systems Corporation. Used with permission.

© 2020 Epic Systems Corporation. Used with permission.
This customized AMS module became available 2 weeks from the admission of our first COVID-19–positive patient, and education on this tool was provided by the AST. The multidisciplinary team members, including attending physicians and fellows, review patients with COVID-19 infection on a daily basis to support and optimize care in conjunction with the primary team.

**Discussion**

As a result of the COVID-19 pandemic, consultants are faced with an unprecedented number of patients to evaluate in a short period. This significant challenge requires consultants to develop new work flows to provide optimal patient care.

Similarly, the AST is challenged with reviewing large numbers of patients, often with limited personnel. Therefore, many ASTs rely on optimizing the EMR to quickly identify and review patients. The use of technology for antimicrobial stewardship has been shown to improve the efficiency in identifying and optimizing the management of patients. With these tools, repurposing the AST workflow and AMS module at our institution allowed us to quickly adapt to the challenges the pandemic posed as our COVID-19 census rapidly exceeded 25% of our total hospital capacity. This workflow offers an efficient way for the consultant to make timely clinical assessments and recommendations including potential therapeutic options, clinical trial enrollment, anticoagulation, monitoring adverse effects from treatment, and antimicrobial use. For the complex COVID-19 cases, a formal infectious disease consultation was recommended if indicated.

In conclusion, during a pandemic such as COVID-19, with a surge in hospitalized patients, alternative mechanisms for patient review may need to be utilized. To help meet this unprecedented challenge, repurposing the existing AMS module and workflow can potentially facilitate appropriate patient review and timely intervention.

**Acknowledgments.** The authors thank Erol Fikrig, MD, Vincent Quagliarello, MD, and the entire Section of Infectious Diseases at Yale for their support of this new and innovative process. We also acknowledge additional members of the COVID-19 treatment team: Zachary Harris, MD, Lauren Pischel, MD, George Goshua, MD, Shana E. Gleeson, MD, Marwan Azar, MD, Insoo Kang, MD, Stuart Seropian, MD, Harvey Rinder, MD, Robert Bona, MD, and Alfred Lee, MD, PhD.

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. Pneumonia of unknown cause—China. World Health Organization website. [https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/](https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/). Published 2020. Accessed April 15, 2020.

2. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514–523.

3. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.

4. Fauci AS, Lane HC, Redfield RR. COVID-19—navigating the uncharted. *N Engl J Med* 2020;382:1268–1269.

5. WHO Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020. World Health Organization website. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020). Published March 11, 2020. Accessed April 15, 2020.

6. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med* 2020;382:929–936.

7. Coronavirus disease 2019 (COVID-19) in the United States. Centers for Disease Control and Prevention website. [https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html). Accessed April 23, 2020.

8. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020 March [Epub ahead of print]. doi:10.1007/s00134-020-05991-x.

9. Kullar R, Goff DA, Schulz LT, Fox BC, Rose WE. The “epic” challenge of optimizing antimicrobial stewardship: the role of electronic medical records and technology. *Clin Infect Dis* 2013;57:1005–1013.